

November 9, 2023

Douglas A. Treco  
Chief Executive Officer  
Inozyme Pharma, Inc.  
321 Summer Street, Suite 400  
Boston, MA 02210

Inc.

Statement on Form S-3

2023

Re: Inozyme Pharma,

Registration

Filed November 7,

File No. 333-275364

Dear Douglas A. Treco:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Howes at 202-551-3370 with any questions.

Please contact Tyler

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Caroline Dotolo, Esq.